VRCA
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Verrica Pharmaceuticals completed enrollment in the first pivotal Phase 3 COVE-2 trial of YCANTH for common warts, with topline data expected in Q1 2027Aug 27, 2026
- Verrica Pharmaceuticals dosed the first U.S. patient in the second pivotal Phase 3 COVE-3 trial of YCANTH for common wartsJun 22, 2026
- Verrica Pharmaceuticals announced the launch of YCANTH in Japan for treating molluscum contagiosum through partner Torii PharmaceuticalFeb 9, 2026
- Verrica Pharmaceuticals dosed first patient in Phase 3 YCANTH program for common wartsJan 7, 2026
- Verrica Pharmaceuticals receives positive feedback from European Medicines Agency supporting clear regulatory path forward to file for approval of YCANTH® in the European UnionOct 21, 2025